U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Submitted for Presentation at the American Society of Hematology (ASH) Annual Meeting First Patient Dosed in the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin ...

The stock rallied as optimism grew over the company's promising pipeline of gene editing therapies, which have been developed based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases. Several clinical milestones are expected later in 2024. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical researc ...

BEAM stock enjoys several positive technical factors that warrant closer investigation. First, Barchart identified the biotech enterprise as a possible J-Hook pattern candidate. The J-Hook is a sinusoidal chart pattern that has attracted attention recently in the field of technical analysis. Featuring an up-down, up-down cycle, at the end of the defined "J" pattern, there's a solid possibility that the asset in question could shoot decisively higher. Barchart only identifies viable candidates after they mee ...

Vertex Pharmaceuticals (VRTX) Source: Pavel Kapysh / Shutterstock.com Vertex Pharmaceuticals (NASDAQ:VRTX) stands out as one of the most seasoned players in the biotech space. Unlike the sea of start-ups in the gene editing field, Vertex boasts a rich legacy in the pharma space, empowering it to leverage its massive financial resources. In recent years, we've seen it dabbling into new areas like gene editing, targeting inflammatory and autoimmune disorders along with certain cancers. Moreover, it collaborat ...

Year to date, shares of Beam Therapeutics have lost 5.8% compared with the industry's decline of 2.7%. As part of the leadership transition process, the company is now looking for a new CFO. Terry-Ann Burrell has been an integral part of BEAM's evolution into a leading gene editing company aimed at developing precision genetic medicines through base editing. Image Source: Zacks Investment Research Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. D ...

"Terry-Ann has been an invaluable member of our team over the last five years, and her leadership was instrumental in the success of our IPO, the build-out of our finance and corporate affairs functions, and the development of Beam's organization and culture," said John Evans, chief executive officer at Beam. "During her tenure, we have successfully raised significant capital to invest in our innovative platform technologies, our manufacturing capabilities, and now our rapidly growing clinical and research ...

Here are some reasons why investors should consider betting on Beam Therapeutics stock. Hematology Program Picking Up Pace: The company is pursuing an ex vivo, autologous transplant-based approach for SCD and beta-thalassemia. It is currently developing BEAM-101 in the phase I/II BEACON study for SCD. Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. Data from multiple patients in the study is expected in the second half of 2024. Image Source: Zack ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. As such, the Zacks rating upgrade for Beam Therapeutics is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future earnings potential, as reflected in earnings estimate revisi ...

VICI stock currently trades at a P/E ratio of just 11x, significantly below the average of 30x for the S&P 500 index. Despite the VICI share price declining 13% year-to-date (YTD), all 21 analysts recommend buying at current levels as the company continues to deliver consistent revenue growth. Jefferies analyst David Katz has a price target with a potential 58% upside from current levels. Identifying stocks capable of increasing investment value 10x can prove tricky. However, those with solid sales growth a ...

With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time. It changes the base instructions of the human body for how the body is maintained and protected. CRISPR Therapeutics (CRSP) When it ...